Cargando...
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
Guardado en:
| Publicado en: | JAMA Intern Med |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Medical Association
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7186918/ https://ncbi.nlm.nih.gov/pubmed/32338703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.1097 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|